- Home
- GILD vs MMC Comparison
GILD vs MMC Comparison
Compare GILD & MMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- MMC
- Stock Information
- Founded
- GILD 1987
- MMC 1871
- Country
- GILD United States
- MMC United States
- Employees
- GILD N/A
- MMC N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- MMC Specialty Insurers
- Sector
- GILD Health Care
- MMC Finance
- Exchange
- GILD Nasdaq
- MMC Nasdaq
- Market Cap
- GILD 113.0B
- MMC 104.0B
- IPO Year
- GILD 1992
- MMC N/A
- Fundamental
- Price
- GILD $91.84
- MMC $215.13
- Analyst Decision
- GILD Buy
- MMC Hold
- Analyst Count
- GILD 26
- MMC 15
- Target Price
- GILD $98.17
- MMC $229.40
- AVG Volume (30 Days)
- GILD 6.6M
- MMC 1.9M
- Earning Date
- GILD 02-11-2025
- MMC 01-30-2025
- Dividend Yield
- GILD 3.35%
- MMC 1.51%
- EPS Growth
- GILD N/A
- MMC 16.97
- EPS
- GILD 0.10
- MMC 8.11
- Revenue
- GILD $28,299,000,000.00
- MMC $23,945,000,000.00
- Revenue This Year
- GILD $6.50
- MMC $8.04
- Revenue Next Year
- GILD $0.36
- MMC $10.44
- P/E Ratio
- GILD $908.39
- MMC $26.55
- Revenue Growth
- GILD 3.31
- MMC 7.84
- 52 Week Low
- GILD $62.07
- MMC $188.31
- 52 Week High
- GILD $98.90
- MMC $235.50
- Technical
- Relative Strength Index (RSI)
- GILD 51.58
- MMC 51.50
- Support Level
- GILD $90.82
- MMC $207.21
- Resistance Level
- GILD $93.07
- MMC $211.95
- Average True Range (ATR)
- GILD 1.54
- MMC 3.16
- MACD
- GILD -0.03
- MMC 0.96
- Stochastic Oscillator
- GILD 56.28
- MMC 78.51
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About MMC Marsh & McLennan Companies Inc.
Marsh McLennan is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (a management and economic consultancy). About half of its revenue is generated outside the US.